^
Association details:
| Biomarker: | KRAS G12C + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Published date:
10/16/2023
Excerpt:
Patients with KRAS p.G12C-mutated advanced or metastatic NSCLC received sotorasib within the German multicenter sotorasib expanded access program between April 2021 to February 2022….Response to sotorasib was lower among patients with a positive PD-L1 expression (TPS ≥1%) and a co-occurring KEAP1 mutation, respectively.
